Body weight increment in patients treated with infliximab for plaque psoriasis. (23rd May 2012)
- Record Type:
- Journal Article
- Title:
- Body weight increment in patients treated with infliximab for plaque psoriasis. (23rd May 2012)
- Main Title:
- Body weight increment in patients treated with infliximab for plaque psoriasis
- Authors:
- Florin, V.
Cottencin, A.C.
Delaporte, E.
Staumont‐Sallé, D. - Abstract:
- Abstract: Background Psoriasis is frequently associated with overweight and obesity. Anti‐TNF‐α therapies are effective in the treatment of psoriasis. TNF‐α is highly involved in body weight regulation. Objective Our objective was to evaluate the increase in weight throughout the treatment with infliximab and the association of weight gain with the body mass index (BMI). Methods Thirty‐five patients affected with severe plaque psoriasis receiving infliximab were included. A control group consisted of 16 patients affected with severe plaque psoriasis and treated with cyclosporine, methotrexate, or acitretin. Assessment of PASI score, body weight and BMI were performed at a 1 and 3‐year follow‐up. Results We observed a body weight increment of 2.5 ± 4.4 kg (mean ± SD) (i.e. + 3.6% of baseline) and 0.1 ± 5 kg (i.e. + 1.2%) in patients treated with infliximab and the control group, respectively ( P = 0.046), after 1 year of treatment. After 3 years of infliximab administration, weight gain was 4.8 ± 5 kg ( n = 16) (i.e. + 6%) ( P = 0.005). Moreover, as classified by BMI, normal weight patients experienced a 4 ± 3.7 kg weight gain (i.e. + 6%) whereas overweight and obese patients had gained 1.3 ± 4.8 kg (i.e. + 1.2%) ( P = 0.039) after 1 year of anti‐TNF‐α therapy. Percentual changes in body weight were larger in normal weight patients at baseline than in overweight/obese counterparts ( P = 0.0149). Conclusion All patients, including normal weight patients, shouldAbstract: Background Psoriasis is frequently associated with overweight and obesity. Anti‐TNF‐α therapies are effective in the treatment of psoriasis. TNF‐α is highly involved in body weight regulation. Objective Our objective was to evaluate the increase in weight throughout the treatment with infliximab and the association of weight gain with the body mass index (BMI). Methods Thirty‐five patients affected with severe plaque psoriasis receiving infliximab were included. A control group consisted of 16 patients affected with severe plaque psoriasis and treated with cyclosporine, methotrexate, or acitretin. Assessment of PASI score, body weight and BMI were performed at a 1 and 3‐year follow‐up. Results We observed a body weight increment of 2.5 ± 4.4 kg (mean ± SD) (i.e. + 3.6% of baseline) and 0.1 ± 5 kg (i.e. + 1.2%) in patients treated with infliximab and the control group, respectively ( P = 0.046), after 1 year of treatment. After 3 years of infliximab administration, weight gain was 4.8 ± 5 kg ( n = 16) (i.e. + 6%) ( P = 0.005). Moreover, as classified by BMI, normal weight patients experienced a 4 ± 3.7 kg weight gain (i.e. + 6%) whereas overweight and obese patients had gained 1.3 ± 4.8 kg (i.e. + 1.2%) ( P = 0.039) after 1 year of anti‐TNF‐α therapy. Percentual changes in body weight were larger in normal weight patients at baseline than in overweight/obese counterparts ( P = 0.0149). Conclusion All patients, including normal weight patients, should receive a dietary intervention. … (more)
- Is Part Of:
- Journal of the European Academy of Dermatology and Venereology. Volume 27:Number 2(2013:Feb.)
- Journal:
- Journal of the European Academy of Dermatology and Venereology
- Issue:
- Volume 27:Number 2(2013:Feb.)
- Issue Display:
- Volume 27, Issue 2 (2013)
- Year:
- 2013
- Volume:
- 27
- Issue:
- 2
- Issue Sort Value:
- 2013-0027-0002-0000
- Page Start:
- e186
- Page End:
- e190
- Publication Date:
- 2012-05-23
- Subjects:
- Dermatology -- Periodicals
Sexually transmitted diseases -- Periodicals
616.5 - Journal URLs:
- https://onlinelibrary.wiley.com/journal/14683083 ↗
http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=jdv ↗
http://www.sciencedirect.com/science/journal/09269959 ↗
http://onlinelibrary.wiley.com/ ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0926-9959;screen=info;ECOIP ↗
http://www.blackwell-synergy.com/loi/jdv ↗ - DOI:
- 10.1111/j.1468-3083.2012.04571.x ↗
- Languages:
- English
- ISSNs:
- 0926-9959
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4741.624000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 20627.xml